moderna vaccine - Search News

FDA refuses review of mRNA flu vaccine

FDA Declines to Review Moderna’s mRNA Flu Vaccine Application

In a major blow to vaccine development, the U.S. Food and Drug Administration (FDA) said it will not review Moderna’s application for the first mRNA-based flu shot.

· 2d

Moderna says FDA refuses its application for new mRNA flu vaccine

· 2d · on MSN

FDA won’t review Moderna application for first mRNA-based flu vaccine

Scientific American · 1d

FDA won’t consider a new mRNA vaccine for flu, despite the technology’s life-saving promise

The U.S. Food and Drug Administration is refusing to consider a new mRNA flu vaccine made by Moderna, the company revealed in a statement on Tuesday.

· 1d

FDA refuses to review Moderna's mRNA flu shot

· 9h

FDA defends its decision to refuse review of Moderna's flu vaccine

· 1d

F.D.A. Refuses to Review Moderna Flu Vaccine

Dr. Vinay Prasad, the agency’s top vaccine regulator, rejected the company’s application for approval over a concern that Moderna’s clinical trial had compared its experimental vaccine against a produ...

· 1d

FDA refuses to review Moderna’s mRNA flu vaccine application

· 1d

Moderna says FDA refuses to review its application for flu vaccine

1don MSN

Moderna’s work developing seasonal vaccines is ‘risky’ under current FDA, analyst says

The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.

24/7 Wall St.

Biotech Turnaround: How Moderna Went From Revenue Collapse to YTD Rally Leader

Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector’s 0.4% YTD return. In fact, Moderna has the 12th-best gains in the entire S&P 500 so far in 2026!

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna

Moderna, Mexico Partner To Boost Local Vaccine Production

Moderna signs a long-term deal with Mexico to build local mRNA production, transfer technology, and supply up to 10 million COVID vaccine doses for the 2025–2026 campaign.

Moderna Shares Climb on Mexican Government Pact for Vaccines

Shares of Moderna gained after the company received a contract to help the Mexican government establish a reliable in-country supply of respiratory vaccines. The stock jumped 6.7% to $44.77 on Tuesday. The shares have risen 40% in the past year.